Diette Gregory B, Fuhlbrigge Anne L, Allen-Ramey Felicia, Hopper April, Sajjan Shiva G, Markson Leona E
Pulmonary and Critical Care Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA.
J Asthma. 2011 Apr;48(3):304-10. doi: 10.3109/02770903.2011.555034. Epub 2011 Feb 28.
Asthma treatment guidelines recommend medications based on the level of asthma control.
To evaluate differences in asthma control between patients who initiated asthma controller monotherapy versus combination therapy.
Children (5-16 years; n = 488) and adults (17-80 years; n = 530) with asthma and no controller therapy in the prior 6 months were included. Telephone surveys were conducted within 5 days of filling a new asthma controller prescription with either the caregiver of children or the adult patient. Demographics, asthma control before therapy, and asthma-related resource use were assessed for patients initiating monotherapy (filling one asthma controller prescription) and combination therapy (filling more than one controller medication or a fixed-dose combination).
Mean pediatric age was 10 years; 53% were male. Mean adult age was 47 years; 25% were male. There were no significant differences in asthma control score between patients receiving monotherapy and combination therapy. Children on combination therapy did not have more nighttime awakening or short-acting β-agonist use but were more likely to have been hospitalized due to asthma attack (p = .05) and have more unscheduled (p = .0374) and scheduled (p = .009) physician visits. Adults on combination therapy were more likely to have been hospitalized due to asthma attack (p < .05) and have regular doctor visits for asthma (p < .01).
Assessment of asthma control scores in the 4 weeks before index medication suggests that asthma severity during a treatment-free period did not differ significantly for patients initiating controller monotherapy versus combination therapy. From these findings, it appears that although physicians may not focus on asthma control when choosing the intensity of initial controller therapy, the intensity of health-care encounters may be an influence.
哮喘治疗指南根据哮喘控制水平推荐用药。
评估起始使用哮喘控制单一疗法与联合疗法的患者在哮喘控制方面的差异。
纳入在过去6个月内未接受控制治疗的哮喘儿童(5 - 16岁;n = 488)和成人(17 - 80岁;n = 530)。在开具新的哮喘控制药物处方后5天内,对儿童的照料者或成年患者进行电话调查。评估起始单一疗法(开具一种哮喘控制药物处方)和联合疗法(开具一种以上控制药物或固定剂量组合)患者的人口统计学特征、治疗前的哮喘控制情况以及与哮喘相关的资源使用情况。
儿童的平均年龄为10岁;53%为男性。成人的平均年龄为47岁;25%为男性。接受单一疗法和联合疗法的患者在哮喘控制评分上无显著差异。接受联合疗法的儿童夜间觉醒次数或短效β受体激动剂的使用次数并未增多,但因哮喘发作住院(p = 0.05)以及计划外(p = 0.0374)和计划内(p = 0.009)就诊的可能性更大。接受联合疗法的成人因哮喘发作住院(p < 0.05)以及定期因哮喘就诊(p < 0.01)的可能性更大。
在起始用药前4周对哮喘控制评分进行评估表明,起始控制单一疗法与联合疗法的患者在无治疗期的哮喘严重程度无显著差异。从这些发现来看,尽管医生在选择初始控制治疗强度时可能未关注哮喘控制情况,但医疗接触的强度可能会产生影响。